CD4 and neoplasm: We already showed that immunization with OMVs engineered with the EGFRvIII tumor-specific B cell epitope (22) and with M30, a mutation-derived CD4+ T cell epitope expressed in B16F10 murine melanoma cells (23), fully prevented tumor growth in C57bl6 mice challenged with B16F10 cells expressing EGRFvIII (24).